<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056740</url>
  </required_header>
  <id_info>
    <org_study_id>21Neuro02</org_study_id>
    <nct_id>NCT05056740</nct_id>
  </id_info>
  <brief_title>Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic</brief_title>
  <acronym>CyBIRD</acronym>
  <official_title>Evaluation of a Combined Analysis of Serum and Cerebrospinal Fluid Inflammatory Biomarkers to Help in Etiological Diagnosis of Central Nervous System Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project rationale:&#xD;
&#xD;
      Since 2017, multiple sclerosis diagnosis should match the new McDonald criteria in which a&#xD;
      &quot;no better explanation than MS&quot; should be fulfilled. However, many patients present with red&#xD;
      flags that lead to a complex diagnostic work-up. There are no available biomarkers that&#xD;
      permit to confirm or roll out MS diagnosis in such cases. Therefore, we lack biological&#xD;
      markers that can help in the diagnosis of patients presenting with suspected MS.&#xD;
&#xD;
      Many studies have found that serum and cerebrospinal fluid (CSF) cytokines could help to&#xD;
      differentiate MS from other diseases such as neuromyelitis optica spectrum disorders (i.e.,&#xD;
      IL-6) or neurosarcoidosis (i.e., sIL-2R). Serum and CSF kappa free light chains have also&#xD;
      shown good diagnosis performance in MS. In daily practice, our MS tertiary center already&#xD;
      perform the analysis of CSF concentrations of IL-1β, sIL-2R, IL-6, IL-10, and serum and CSF&#xD;
      kappa and lambda free light chains to roll out other central nervous system (CNS) autoimmune&#xD;
      diseases in patients presenting with white matter hyperintensities (WMH).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To correlate CSF IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains&#xD;
      with the final diagnosis in patients presenting to our MS tertiary center with suspected MS&#xD;
      to identify a specific inflammatory biomarker profil involved in MS and other CNS autoimmune&#xD;
      diseases.&#xD;
&#xD;
      The methodology:&#xD;
&#xD;
      This is an observational study. All patients ongoing a routine diagnostic work-up for&#xD;
      suspected MS from june 2020 to june 2022 in our MS tertiary center will be analyzed.&#xD;
      Cerebrospinal fluid IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light&#xD;
      chains will be correlated with the final diagnosis to ultimately find MS associated&#xD;
      biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify specific biomarkers profil in MS group</measure>
    <time_frame>1 day</time_frame>
    <description>Quantification in each group of patients of IL-1beta, soluble receptor of IL-2, IL-6 and IL-10 by ELISA and cerebrospinal fluid/serum kappa and lambda free light chains by using the turbidimetric analyzer Optilite (BindingSite).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>MS</arm_group_label>
    <description>Patients with a definite MS diagnosis according to the 2017 McDonald criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red-flag MS</arm_group_label>
    <description>Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other CNS autoimmune diseases</arm_group_label>
    <description>Patients with a definite diagnostic of CNS autoimmune disease that is not MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients with a definite diagnostic of non-inflammatory CNS disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Data analysis</intervention_name>
    <description>Analysis of the data from routine care at the end of the diagnostic work-up</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>MS</arm_group_label>
    <arm_group_label>Other CNS autoimmune diseases</arm_group_label>
    <arm_group_label>Red-flag MS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred to our MS tertiary center for the diagnostic work-up of white matter&#xD;
        hyperintensities suggestive of underlying inflammatory demyelinating disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred to our center for the diagnostic work-up of suspected MS&#xD;
&#xD;
          -  Patients that need a routine blood analysis&#xD;
&#xD;
          -  Patients that need a routine CSF analysis&#xD;
&#xD;
          -  Non opposition to research consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a contraindication to perform spinal tap (increase bleeding risk&#xD;
             medicine or disease)&#xD;
&#xD;
          -  Patients with a contraindication to MRI (metal prosthesis…)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Levraut, MD</last_name>
      <phone>+33492034126</phone>
      <email>levraut.m@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

